Symbols / EBS Stock $8.03 -0.74% Emergent BioSolutions Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NYQ
EBS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
Exch · Country NYQ · United States
Market Cap 414.71M
Enterprise Value 794.02M
Income 52.60M
Sales 742.90M
FCF (ttm) 205.39M
Book/sh 10.03
Cash/sh 3.97
Employees 900
Insider 10d —
IPO Nov 15, 2006
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 8.63
Forward P/E 2.69
PEG 0.38
P/S 0.56
P/B 0.80
P/C —
EV/EBITDA 3.80
EV/Sales 1.07
Quick Ratio 2.19
Current Ratio 5.01
Debt/Eq 111.69
LT Debt/Eq —
EPS (ttm) 0.93
EPS next Y 2.99
EPS Growth —
Revenue Growth -23.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-02-26
ROA 5.33%
ROE 10.46%
ROIC —
Gross Margin 49.44%
Oper. Margin -15.20%
Profit Margin 7.08%
Shs Outstand 51.64M
Shs Float 47.11M
Insider Own 1.89%
Instit Own 82.26%
Short Float 18.97%
Short Ratio 12.21
Short Interest 9.64M
52W High 14.06
vs 52W High -42.89%
52W Low 4.71
vs 52W Low 70.49%
Beta 2.36
Impl. Vol. 1.11%
Rel Volume 0.38
Avg Volume 836.87K
Volume 321.69K
Target (mean) $12.00
Tgt Median $12.00
Tgt Low $12.00
Tgt High $12.00
# Analysts 2
Recom None
Prev Close $8.09
Price $8.03
Change -0.74%
About

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.00
Mean price target
2. Current target
$8.03
Latest analyst target
3. DCF / Fair value
$71.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.03
Low
$12.00
High
$12.00
Mean
$12.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-09 main HC Wainwright & Co. Buy → Buy $12
2025-12-16 reit HC Wainwright & Co. Buy → Buy $15
2025-09-03 reit HC Wainwright & Co. Buy → Buy $15
2025-04-01 reit HC Wainwright & Co. Buy → Buy $15
2025-03-21 reit HC Wainwright & Co. Buy → Buy $15
2025-03-04 reit HC Wainwright & Co. Buy → Buy $15
2025-01-21 reit HC Wainwright & Co. Buy → Buy $15
2025-01-10 reit HC Wainwright & Co. Buy → Buy $15
2024-12-30 init HC Wainwright & Co. — → Buy $15
2024-11-07 main Benchmark Buy → Buy $12
2024-09-13 reit Rodman & Renshaw Buy → Buy $16
2024-08-22 init Rodman & Renshaw — → Buy $16
2024-08-16 reit Benchmark Buy → Buy $8
2024-08-09 reit Benchmark Buy → Buy $8
2024-07-03 reit Benchmark Buy → Buy $8
2024-07-02 reit Benchmark Buy → Buy $8
2024-06-24 reit Benchmark Buy → Buy $8
2024-06-21 reit Benchmark Buy → Buy $8
2024-06-20 main Benchmark Buy → Buy $8
2024-04-11 reit Benchmark Buy → Buy $5
News
RSS: Latest EBS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 WILLIAMS PAUL ANTHONY Officer — 4,000 $8.44 $33,760
2026-03-03 FOWLER JOHN D JR Director — 5,006 $8.99 $45,004
2025-12-05 RICHARD RONALD B Director — 21,984 $11.90 $263,077
2025-12-05 RICHARD RONALD B Director — 25,748 $5.02 $129,255
2025-11-10 DEGOLYER DONALD W Director — 17,801 $10.54 $187,623
2025-11-07 DAYAL SUJATA TYAGI Director — 8,552 $10.00 $85,520
2025-10-07 GLESSNER COLEEN Officer — 30,608 $10.00 $306,080
2025-08-15 ZOON KATHRYN C. Director — 7,086 $8.87 $62,853
2025-08-12 DEGOLYER DONALD W Director — 7,844 $8.65 $67,831
2025-05-23 KATKIN KEITH A Director — 7,844 $6.30 $49,417
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
705.20
-30.43%
1,013.60
-0.92%
1,023.00
-4.93%
1,076.10
Operating Revenue
705.20
-30.43%
1,013.60
-0.92%
1,023.00
-4.93%
1,076.10
Cost Of Revenue
326.20
-52.12%
681.30
-3.42%
705.40
+1.77%
693.10
Reconciled Cost Of Revenue
295.50
-53.65%
637.60
-1.29%
645.90
+5.94%
609.70
Gross Profit
379.00
+14.05%
332.30
+4.63%
317.60
-17.08%
383.00
Operating Expense
266.70
-35.55%
413.80
-20.29%
519.10
-4.98%
546.30
Research And Development
53.20
-24.75%
70.70
-36.54%
111.40
-40.84%
188.30
Selling General And Administration
186.10
-39.58%
308.00
-16.40%
368.40
+8.51%
339.50
Other Operating Expenses
-37.70
-25.67%
-30.00
-14.07%
-26.30
+36.47%
-41.40
Total Expenses
592.90
-45.86%
1,095.10
-10.57%
1,224.50
-1.20%
1,239.40
Operating Income
112.30
+237.79%
-81.50
+59.55%
-201.50
-23.39%
-163.30
Total Operating Income As Reported
100.10
+192.09%
-108.70
+85.04%
-726.40
-327.29%
-170.00
EBITDA
237.90
+544.72%
36.90
+107.12%
-518.20
-1249.48%
-38.40
Normalized EBITDA
262.30
+569.13%
39.20
+156.00%
-70.00
-120.82%
-31.70
Reconciled Depreciation
95.80
-11.95%
108.80
-13.03%
125.10
-12.70%
143.30
EBIT
142.10
+297.64%
-71.90
+88.82%
-643.30
-254.05%
-181.70
Total Unusual Items
-24.40
-960.87%
-2.30
+99.49%
-448.20
-6589.55%
-6.70
Total Unusual Items Excluding Goodwill
-24.40
-960.87%
-2.30
+99.49%
-448.20
-6589.55%
-6.70
Special Income Charges
-24.40
-960.87%
-2.30
+99.49%
-448.20
-6589.55%
-6.70
Other Special Charges
12.20
+2133.33%
-0.60
+76.00%
-2.50
—
Impairment Of Capital Assets
12.20
-55.15%
27.20
-94.82%
524.90
+7734.33%
6.70
Net Income
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Pretax Income
82.80
+157.94%
-142.90
+80.46%
-731.20
-233.88%
-219.00
Net Non Operating Interest Income Expense
-59.30
+16.48%
-71.00
+19.23%
-87.90
-135.66%
-37.30
Interest Expense Non Operating
59.30
-16.48%
71.00
-19.23%
87.90
+135.66%
37.30
Net Interest Income
-59.30
+16.48%
-71.00
+19.23%
-87.90
-135.66%
-37.30
Interest Expense
59.30
-16.48%
71.00
-19.23%
87.90
+135.66%
37.30
Other Income Expense
29.80
+210.42%
9.60
+102.17%
-441.80
-2301.09%
-18.40
Other Non Operating Income Expenses
54.20
+355.46%
11.90
+85.94%
6.40
+154.70%
-11.70
Gain On Sale Of Business
0.00
-100.00%
24.30
-67.25%
74.20
0.00
Tax Provision
30.20
-36.69%
47.70
+62.80%
29.30
+495.95%
-7.40
Tax Rate For Calcs
0.00
+73.81%
0.00
+0.00%
0.00
+600.00%
0.00
Tax Effect Of Unusual Items
-8.91
-1743.89%
-0.48
+99.49%
-94.12
-46726.87%
-0.20
Net Income Including Noncontrolling Interests
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Net Income From Continuing Operation Net Minority Interest
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Net Income From Continuing And Discontinued Operation
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Net Income Continuous Operations
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Normalized Income
68.09
+136.07%
-188.78
+53.55%
-406.42
-98.16%
-205.10
Net Income Common Stockholders
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Diluted EPS
0.93
+125.83%
-3.60
+75.76%
-14.85
-232.21%
-4.47
Basic EPS
0.98
+127.22%
-3.60
+75.76%
-14.85
-232.21%
-4.47
Basic Average Shares
53.50
+0.94%
53.00
+3.52%
51.20
+2.20%
50.10
Diluted Average Shares
56.70
+6.98%
53.00
+3.52%
51.20
+2.20%
50.10
Diluted NI Availto Com Stockholders
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Amortization
65.10
+0.00%
65.10
-0.76%
65.60
+9.52%
59.90
Amortization Of Intangibles Income Statement
65.10
+0.00%
65.10
-0.76%
65.60
+9.52%
59.90
Depreciation Amortization Depletion Income Statement
65.10
+0.00%
65.10
-0.76%
65.60
+9.52%
59.90
Depreciation And Amortization In Income Statement
65.10
+0.00%
65.10
-0.76%
65.60
+9.52%
59.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,318.60
-5.12%
1,389.70
-23.78%
1,823.20
-42.42%
3,166.30
Current Assets
662.50
+10.66%
598.70
-11.89%
679.50
-43.86%
1,210.40
Cash Cash Equivalents And Short Term Investments
205.40
+106.43%
99.50
-10.92%
111.70
-82.62%
642.60
Cash And Cash Equivalents
205.40
+106.43%
99.50
-10.92%
111.70
-82.62%
642.60
Receivables
84.20
-45.50%
154.50
-19.11%
191.00
+19.97%
159.20
Accounts Receivable
66.80
-50.66%
135.40
-4.51%
141.80
+38.07%
102.70
Gross Accounts Receivable
66.80
-50.66%
135.40
-4.51%
141.80
+38.07%
102.70
Allowance For Doubtful Accounts Receivable
—
—
—
-0.70
Receivables Adjustments Allowances
-0.80
-60.00%
-0.50
+77.27%
-2.20
-214.29%
-0.70
Other Receivables
18.20
-7.14%
19.60
-61.87%
51.40
-10.14%
57.20
Inventory
343.40
+10.17%
311.70
-5.23%
328.90
-6.22%
350.70
Raw Materials
120.60
+25.76%
95.90
-25.49%
128.70
-9.56%
142.30
Work In Process
109.00
+26.30%
86.30
-23.83%
113.30
-2.50%
116.20
Finished Goods
113.80
-12.12%
129.50
+49.02%
86.90
-5.75%
92.20
Prepaid Assets
—
—
—
—
Restricted Cash
3.70
-39.34%
6.10
0.00
0.00
Other Current Assets
25.80
-4.09%
26.90
-43.84%
47.90
-17.27%
57.90
Total Non Current Assets
656.10
-17.05%
791.00
-30.84%
1,143.70
-41.53%
1,955.90
Net PPE
205.40
-24.09%
270.60
-29.31%
382.80
-53.18%
817.60
Gross PPE
509.50
-23.69%
667.70
-15.93%
794.20
-33.89%
1,201.40
Accumulated Depreciation
-304.10
+23.42%
-397.10
+3.48%
-411.40
-7.19%
-383.80
Properties
0.00
0.00
0.00
0.00
Land And Improvements
20.70
-19.77%
25.80
-14.00%
30.00
-45.36%
54.90
Buildings And Improvements
160.50
-18.15%
196.10
-14.70%
229.90
-29.89%
327.90
Machinery Furniture Equipment
321.70
-26.13%
435.50
-12.48%
497.60
-21.40%
633.10
Construction In Progress
6.60
-35.92%
10.30
-71.93%
36.70
-80.22%
185.50
Goodwill And Other Intangible Assets
436.50
-12.96%
501.50
-11.49%
566.60
-40.17%
947.00
Goodwill
—
—
0.00
-100.00%
218.20
Other Intangible Assets
436.50
-12.96%
501.50
-11.49%
566.60
-22.26%
728.80
Other Non Current Assets
14.20
-24.87%
18.90
-90.27%
194.30
+1.57%
191.30
Total Liabilities Net Minority Interest
796.00
-12.23%
906.90
-22.74%
1,173.90
-34.00%
1,778.60
Current Liabilities
132.20
-18.60%
162.40
-75.07%
651.30
-47.00%
1,228.90
Payables And Accrued Expenses
74.60
-11.61%
84.40
-35.47%
130.80
-5.49%
138.40
Payables
62.40
-6.45%
66.70
-40.55%
112.20
+8.41%
103.50
Accounts Payable
55.60
-8.70%
60.90
-45.72%
112.20
+8.41%
103.50
Current Accrued Expenses
12.20
-31.07%
17.70
-4.84%
18.60
-46.70%
34.90
Pensionand Other Post Retirement Benefit Plans Current
41.80
-25.49%
56.10
-24.29%
74.10
-15.12%
87.30
Total Tax Payable
6.80
+17.24%
5.80
—
—
Current Debt And Capital Lease Obligation
—
—
413.70
-56.78%
957.30
Current Debt
—
—
413.70
-56.78%
957.30
Other Current Liabilities
15.80
-27.85%
21.90
-33.03%
32.70
-28.76%
45.90
Total Non Current Liabilities Net Minority Interest
663.80
-10.84%
744.50
+42.46%
522.60
-4.93%
549.70
Long Term Debt And Capital Lease Obligation
572.10
-13.80%
663.70
+48.65%
446.50
-0.45%
448.50
Long Term Debt
572.10
-13.80%
663.70
+48.65%
446.50
-0.45%
448.50
Non Current Deferred Liabilities
37.80
-9.35%
41.70
-11.65%
47.20
-20.94%
59.70
Non Current Deferred Revenue
—
—
—
—
Non Current Deferred Taxes Liabilities
37.80
-9.35%
41.70
-11.65%
47.20
-20.94%
59.70
Other Non Current Liabilities
53.90
+37.85%
39.10
+35.29%
28.90
-30.36%
41.50
Stockholders Equity
522.60
+8.24%
482.80
-25.64%
649.30
-53.21%
1,387.70
Common Stock Equity
522.60
+8.24%
482.80
-25.64%
649.30
-53.21%
1,387.70
Capital Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Common Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
60.80
+1.45%
59.93
+3.68%
57.80
+3.77%
55.70
Ordinary Shares Number
52.10
-4.10%
54.33
+4.08%
52.20
+4.19%
50.10
Treasury Shares Number
8.70
+55.36%
5.60
+0.00%
5.60
+0.00%
5.60
Additional Paid In Capital
942.40
+1.55%
928.00
+2.61%
904.40
+3.54%
873.50
Retained Earnings
-159.80
+24.76%
-212.40
-874.31%
-21.80
-102.95%
738.70
Gains Losses Not Affecting Retained Earnings
-7.50
-44.23%
-5.20
+8.77%
-5.70
-283.87%
3.10
Treasury Stock
252.60
+10.94%
227.70
+0.00%
227.70
+0.00%
227.70
Other Equity Adjustments
-7.50
-44.23%
-5.20
+8.77%
-5.70
-283.87%
3.10
Total Equity Gross Minority Interest
522.60
+8.24%
482.80
-25.64%
649.30
-53.21%
1,387.70
Total Capitalization
1,094.70
-4.52%
1,146.50
+4.63%
1,095.80
-40.32%
1,836.20
Working Capital
530.30
+21.54%
436.30
+1447.16%
28.20
+252.43%
-18.50
Invested Capital
1,094.70
-4.52%
1,146.50
-24.05%
1,509.50
-45.96%
2,793.50
Total Debt
572.10
-13.80%
663.70
-22.84%
860.20
-38.81%
1,405.80
Net Debt
366.70
-35.01%
564.20
-24.62%
748.50
-1.93%
763.20
Net Tangible Assets
86.10
+560.43%
-18.70
-122.61%
82.70
-81.23%
440.70
Tangible Book Value
86.10
+560.43%
-18.70
-122.61%
82.70
-81.23%
440.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
170.60
+190.63%
58.70
+128.45%
-206.30
-504.99%
-34.10
Cash Flow From Continuing Operating Activities
170.60
+190.63%
58.70
+128.45%
-206.30
-504.99%
-34.10
Net Income From Continuing Operations
52.60
+127.60%
-190.60
+74.94%
-760.50
-259.40%
-211.60
Depreciation Amortization Depletion
95.80
-11.95%
108.80
-13.03%
125.10
-12.70%
143.30
Depreciation
30.70
-29.75%
43.70
-26.55%
59.50
-28.66%
83.40
Amortization Cash Flow
65.10
+0.00%
65.10
-0.76%
65.60
+9.52%
59.90
Depreciation And Amortization
95.80
-11.95%
108.80
-13.03%
125.10
-12.70%
143.30
Amortization Of Intangibles
65.10
+0.00%
65.10
-0.76%
65.60
+9.52%
59.90
Other Non Cash Items
10.20
-29.66%
14.50
+8.21%
13.40
+41.05%
9.50
Stock Based Compensation
16.20
-10.00%
18.00
-22.08%
23.10
-48.78%
45.10
Asset Impairment Charge
12.20
-55.15%
27.20
-94.82%
524.90
+7734.33%
6.70
Deferred Tax
-4.00
+27.27%
-5.50
+38.20%
-8.90
+68.88%
-28.60
Deferred Income Tax
-4.00
+27.27%
-5.50
+38.20%
-8.90
+68.88%
-28.60
Operating Gains Losses
10.00
+516.67%
-2.40
+95.48%
-53.10
-1575.00%
3.60
Gain Loss On Investment Securities
5.50
+400.00%
1.10
—
—
Change In Working Capital
-22.40
-125.25%
88.70
+226.17%
-70.30
-3247.62%
-2.10
Change In Receivables
25.50
+204.51%
-24.40
-12.96%
-21.60
-118.29%
118.10
Changes In Account Receivables
25.50
+204.51%
-24.40
-12.96%
-21.60
-118.29%
118.10
Change In Inventory
-30.30
-23.67%
-24.50
-4183.33%
0.60
+101.05%
-57.10
Change In Prepaid Assets
11.70
-93.11%
169.90
+1352.14%
11.70
+158.79%
-19.90
Change In Payables And Accrued Expense
-35.90
+7.71%
-38.90
+29.91%
-55.50
+31.90%
-81.50
Change In Accrued Expense
-27.50
-366.10%
-5.90
+91.07%
-66.10
+2.07%
-67.50
Change In Payable
-8.40
+74.55%
-33.00
-411.32%
10.60
+175.71%
-14.00
Change In Account Payable
-8.40
+74.55%
-33.00
-411.32%
10.60
+175.71%
-14.00
Change In Other Working Capital
6.60
+0.00%
6.60
+220.00%
-5.50
-114.36%
38.30
Investing Cash Flow
69.40
-44.57%
125.20
-41.03%
212.30
+155.68%
-381.30
Cash Flow From Continuing Investing Activities
69.40
-44.57%
125.20
-41.03%
212.30
+155.68%
-381.30
Net PPE Purchase And Sale
24.40
+262.67%
-15.00
+70.93%
-51.60
+55.44%
-115.80
Purchase Of PPE
-13.80
+39.74%
-22.90
+55.62%
-51.60
+55.44%
-115.80
Sale Of PPE
38.20
+383.54%
7.90
0.00
0.00
Capital Expenditure
-13.80
+39.74%
-22.90
+55.62%
-51.60
+55.44%
-115.80
Net Business Purchase And Sale
0.00
-100.00%
110.20
-59.22%
270.20
0.00
Gain Loss On Sale Of Business
0.00
+100.00%
-32.20
+56.60%
-74.20
0.00
Net Intangibles Purchase And Sale
—
—
—
-21.80
Purchase Of Intangibles
—
—
—
-21.80
Net Other Investing Changes
45.00
+50.00%
30.00
+576.19%
-6.30
+97.63%
-265.50
Financing Cash Flow
-136.60
+28.11%
-190.00
+64.53%
-535.70
-211.33%
481.20
Cash Flow From Continuing Financing Activities
-136.60
+28.11%
-190.00
+64.53%
-535.70
-211.33%
481.20
Net Issuance Payments Of Debt
-108.70
+45.21%
-198.40
+63.49%
-543.40
-196.31%
564.20
Issuance Of Debt
0.00
-100.00%
284.00
+1320.00%
20.00
-96.66%
598.00
Repayment Of Debt
-108.70
+77.47%
-482.40
+14.38%
-563.40
-1566.86%
-33.80
Long Term Debt Issuance
0.00
-100.00%
284.00
+1320.00%
20.00
-96.66%
598.00
Long Term Debt Payments
-108.70
+77.47%
-482.40
+14.38%
-563.40
-1566.86%
-33.80
Net Long Term Debt Issuance
-108.70
+45.21%
-198.40
+63.49%
-543.40
-196.31%
564.20
Short Term Debt Issuance
—
—
—
598.00
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
598.00
Net Common Stock Issuance
-24.90
-367.74%
9.30
+10.71%
8.40
+110.23%
-82.10
Common Stock Payments
-24.90
0.00
0.00
+100.00%
-82.10
Repurchase Of Capital Stock
-24.90
0.00
0.00
+100.00%
-82.10
Proceeds From Stock Option Exercised
2.20
-85.23%
14.90
+727.78%
1.80
-64.00%
5.00
Net Other Financing Charges
-5.20
+67.09%
-15.80
-532.00%
-2.50
+57.63%
-5.90
Changes In Cash
103.40
+1795.08%
-6.10
+98.85%
-529.70
-905.02%
65.80
Effect Of Exchange Rate Changes
0.10
0.00
+100.00%
-1.20
-340.00%
0.50
Beginning Cash Position
105.60
-5.46%
111.70
-82.62%
642.60
+11.50%
576.30
End Cash Position
209.10
+98.01%
105.60
-5.46%
111.70
-82.62%
642.60
Free Cash Flow
156.80
+337.99%
35.80
+113.88%
-257.90
-72.05%
-149.90
Interest Paid Supplemental Data
49.70
-22.34%
64.00
-6.30%
68.30
+106.97%
33.00
Income Tax Paid Supplemental Data
40.00
+50.94%
26.50
-49.81%
52.80
+751.61%
6.20
Common Stock Issuance
0.00
-100.00%
9.30
+10.71%
8.40
0.00
Issuance Of Capital Stock
0.00
-100.00%
9.30
+10.71%
8.40
0.00
Sale Of Business
0.00
-100.00%
110.20
-59.22%
270.20
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category